BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ: INVA) announced today that it will report
financial results for the third quarter ended September 30, 2016 after
market close on Thursday, October 27, 2016. Innoviva management will
host a webcast and conference call at 5:00 p.m. EDT that day to discuss
the financial results and provide a corporate update.
To participate in the live call dial (877) 837-3908 from the U.S., or
(973) 890-8166 for international callers and enter Conference ID:
97037854. A live webcast of the call will be available at: http://edge.media-server.com/m/p/6stsppn8
or from the investor relations section of the company website at www.inva.com
and will be archived for 30 days. A telephone replay of the call will be
available through Nov. 3, 2016, by dialing (855) 859-2056 from the U.S.,
or (404) 537-3406 for international callers and entering Conference ID:
97037854.
About Innoviva
Innoviva is focused on bringing compelling new medicines to patients in
areas of unmet need by leveraging its significant expertise in the
development, commercialization and financial management of
bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory
assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO®
ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva
and GSK. Under the agreement with GSK, Innoviva is eligible to receive
associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®
and, if approved and commercialized, VI monotherapy, as well. In
addition, Innoviva retains a 15 percent economic interest in future
payments made by GSK for earlier-stage programs partnered with
Theravance Biopharma, Inc. For more information, please visit Innoviva's
website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161019005025/en/
Innoviva, Inc.
Eric d'Esparbes
Senior Vice President and Chief
Financial Officer
650-238-9640
investor.relations@thrxinc.com
Source: Innoviva, Inc.
News Provided by Acquire Media